Search research articles
Contact Us
Filters
Showing results (101-110 of 117) with videos related to
Page
of 12
Sort By:
Molecular Cancer Therapeutics
|
July 19, 2017
Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer
Josep Tabernero, Atsushi Ohtsu, Kei Muro, et al.
American Journal of Cancer Research
|
February 13, 2023
Clinical features of patients with <i>MTAP</i>-deleted bladder cancer
Andre L De Souza, Anthony E Mega, John Douglass, et al.
British Journal of Cancer
|
September 14, 2016
Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab
Charles S Fuchs, Josep Tabernero, Jiří Tomášek, et al.
Journal of Gastric Cancer
|
July 7, 2017
Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data
Charles S Fuchs, Kei Muro, Jiri Tomasek, et al.
International Journal of Radiation Oncology, Biology, Physics
|
August 29, 2020
Impact of Diabetes and Insulin Use on Prognosis in Patients With Resected Pancreatic Cancer: An Ancillary Analysis of NRG Oncology RTOG 9704
Danielle S Bitterman, Kathryn A Winter, Theodore S Hong, et al.
Journal for Immunotherapy of Cancer
|
February 6, 2019
Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial
Hyun Cheol Chung, Hendrik-Tobias Arkenau, Jeeyun Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 16, 2020
Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100
Markus Moehler, Mikhail Dvorkin, Narikazu Boku, et al.
Biorxiv : the Preprint Server for Biology
|
August 15, 2020
Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells
Lanlan Zhou, Kelsey Huntington, Shengliang Zhang, et al.
Oncotarget
|
November 27, 2020
MEK inhibitors reduce cellular expression of ACE2, pERK, pRb while stimulating NK-mediated cytotoxicity and attenuating inflammatory cytokines relevant to SARS-CoV-2 infection
Lanlan Zhou, Kelsey Huntington, Shengliang Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 20, 2023
Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies
Benedito A Carneiro, Ludimila Cavalcante, Devalingam Mahalingam, et al.
Page
of 12
Search research articles
Search
Showing results (101-110 of 117) with videos related to
Sort By:
Page
of 12
Molecular Cancer Therapeutics
|
July 19, 2017
Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer
Josep Tabernero, Atsushi Ohtsu, Kei Muro, et al.
American Journal of Cancer Research
|
February 13, 2023
Clinical features of patients with <i>MTAP</i>-deleted bladder cancer
Andre L De Souza, Anthony E Mega, John Douglass, et al.
British Journal of Cancer
|
September 14, 2016
Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab
Charles S Fuchs, Josep Tabernero, Jiří Tomášek, et al.
Journal of Gastric Cancer
|
July 7, 2017
Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data
Charles S Fuchs, Kei Muro, Jiri Tomasek, et al.
International Journal of Radiation Oncology, Biology, Physics
|
August 29, 2020
Impact of Diabetes and Insulin Use on Prognosis in Patients With Resected Pancreatic Cancer: An Ancillary Analysis of NRG Oncology RTOG 9704
Danielle S Bitterman, Kathryn A Winter, Theodore S Hong, et al.
Journal for Immunotherapy of Cancer
|
February 6, 2019
Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial
Hyun Cheol Chung, Hendrik-Tobias Arkenau, Jeeyun Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 16, 2020
Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100
Markus Moehler, Mikhail Dvorkin, Narikazu Boku, et al.
Biorxiv : the Preprint Server for Biology
|
August 15, 2020
Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells
Lanlan Zhou, Kelsey Huntington, Shengliang Zhang, et al.
Oncotarget
|
November 27, 2020
MEK inhibitors reduce cellular expression of ACE2, pERK, pRb while stimulating NK-mediated cytotoxicity and attenuating inflammatory cytokines relevant to SARS-CoV-2 infection
Lanlan Zhou, Kelsey Huntington, Shengliang Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 20, 2023
Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies
Benedito A Carneiro, Ludimila Cavalcante, Devalingam Mahalingam, et al.
Page
of 12